NO20072576L - CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft - Google Patents

CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft

Info

Publication number
NO20072576L
NO20072576L NO20072576A NO20072576A NO20072576L NO 20072576 L NO20072576 L NO 20072576L NO 20072576 A NO20072576 A NO 20072576A NO 20072576 A NO20072576 A NO 20072576A NO 20072576 L NO20072576 L NO 20072576L
Authority
NO
Norway
Prior art keywords
breast cancer
antibody
aromatase inhibitor
ctla
combination therapy
Prior art date
Application number
NO20072576A
Other languages
English (en)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20072576L publication Critical patent/NO20072576L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører administrering av et anti-CTLA4-antistoff, spesielt humane antistoffer mot humant CTLA4, slik som de som har aminosyresekvenser til antistoffer 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9. 1.1 og I ODI (MDX-010), i kombinasjon med en aromatasehemmer, for behandlingen av brystcancer. Mer bestemt vedrører oppfinnelsen administrering av et anti-CTLA4antistoff og eksemestan for behandling av brystcancer.
NO20072576A 2004-11-04 2007-05-21 CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft NO20072576L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62485604P 2004-11-04 2004-11-04
PCT/IB2005/003307 WO2006048749A1 (en) 2004-11-04 2005-10-24 Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer

Publications (1)

Publication Number Publication Date
NO20072576L true NO20072576L (no) 2007-08-03

Family

ID=35825412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072576A NO20072576L (no) 2004-11-04 2007-05-21 CTLA-4 antistoff og aromataseinhibitor eller kombinasjonsbehandling for brystkreft

Country Status (15)

Country Link
EP (1) EP1819735A1 (no)
JP (1) JP2008518902A (no)
KR (1) KR20070067702A (no)
CN (1) CN101052655A (no)
AR (1) AR053651A1 (no)
AU (1) AU2005300315A1 (no)
BR (1) BRPI0515735A2 (no)
CA (1) CA2586844A1 (no)
IL (1) IL182244A0 (no)
MX (1) MX2007003804A (no)
NO (1) NO20072576L (no)
RU (1) RU2007114111A (no)
TW (1) TW200621804A (no)
WO (1) WO2006048749A1 (no)
ZA (1) ZA200702577B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
WO2007008463A2 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
DK2346995T3 (en) 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
HUE044352T2 (hu) 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
CN103768596B (zh) * 2012-10-17 2016-06-22 苏州丁孚靶点生物技术有限公司 用于肿瘤治疗的组合产品、其用途及相关方法
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
CN105025884B (zh) 2013-03-01 2019-08-20 阿斯泰克斯制药公司 药物组合
MX377714B (es) * 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
AU2016317936A1 (en) 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN106883298B (zh) 2015-12-16 2021-12-17 上海康岱生物医药技术股份有限公司 双特异性偶联抗体及其制法和用途
EP3400291B2 (en) 2016-01-08 2024-02-28 Replimune Limited Engineered virus
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3505183B1 (en) * 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018167780A1 (en) * 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
WO2021173870A1 (en) * 2020-02-27 2021-09-02 University Of Washington Composition and method to prepare long-acting injectable suspension containing multiple cancer drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies

Also Published As

Publication number Publication date
JP2008518902A (ja) 2008-06-05
KR20070067702A (ko) 2007-06-28
IL182244A0 (en) 2007-09-20
CA2586844A1 (en) 2006-05-11
EP1819735A1 (en) 2007-08-22
MX2007003804A (es) 2007-04-23
TW200621804A (en) 2006-07-01
RU2007114111A (ru) 2008-12-10
CN101052655A (zh) 2007-10-10
ZA200702577B (en) 2008-07-30
AR053651A1 (es) 2007-05-16
AU2005300315A1 (en) 2006-05-11
BRPI0515735A2 (pt) 2011-10-11
WO2006048749A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
NO20056236L (no) Behandling med anti-VEGF-antistoffer
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
NO20054769L (no) Substituerte fenylalkansyrer
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
NO20054958L (no) Substitulerte aminokarboksylsyrer
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
EA201000424A1 (ru) Антитела к il-23
NO20072951L (no) Behandling av et intestinalt adenom og/eller adenokarsinom ved hemming av Notch-reaksjonsveiaktivering
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
NO20070091L (no) Sukkerbelegg og fremgangsmate for dette
NO341574B1 (no) Forbindelse, farmasøytisk sammensetning og sett for behandling av cancer eller i en avbildningsmetode.
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application